MIRA INFORM REPORT

 

 

Report Date :

20th June 2006

 

IDENTIFICATION DETAILS

 

Name :

HAWON BIOCHEMICAL SCIENCE CO. LTD.

 

 

Registered Office :

404-18, Nojang-ri, Jeondong-myeon, Yeongi-gun, Chungcheongnam-do, Korea

 

 

Country :

Korea

 

 

Financials (as on) :

31/12/2001

 

 

Date of Incorporation :

11/29/1996

 

 

Legal Form :

Co., Ltd by shares

 

 

Line of Business :

Wholesalers of Medicine and Medical Goods

 

RATING & COMMENTS

 

MIRA’s Rating :

B

 

RATING

STATUS

PROPOSED CREDIT LINE

26-40

B

Unfavourable & favourable factors carry similar weight in credit consideration. Capability to overcome financial difficulties seems comparatively below average/normal.

Small

 

Status :

Moderate

 

 

Payment Behaviour :

Unknown

 

 

Litigation :

Clear

 

 

Ⅰ. Basic Information

 

Basic

 

Company Name

Hawon Biochemical Science Co. Ltd.

Address

404-18, Nojang-ri, Jeondong-myeon, Yeongi-gun, Chungcheongnam-do, Korea

Building

 

Zip Code

339-841

Tel

+82-41-862-2681

Fax

+82-41-862-2686

E-mail

 

Website

 

Other Address

 

Tel

 

Fax

 

Type

Export/Import

Industry

Wholesale of Medicine and Medical Goods

  Main Business

 

  Sub Business

 

Established (mm/dd/yyyy)

11/29/1996

 

 

Detailed Products

 

Activity

Detailed Products (UNSPSC)

Sell

Drugs and Pharmaceutical Products(51000000)

 

 

 

 

 

 

 

 

Others

 

Name

Koo Ja-Choon

Address

29-7, Samseon-dong 3(sam)-ga, Seongbuk-gu, Seoul, 136-043 Korea

Date of Birth (mm/dd/yyyy)

08/26/1935

Title

President

Sex

Male

Nationality

Korean

Capital

2,000,000,000KRW

Employees

17

Formation

Co., Ltd by shares

 

 

 

Ⅱ. Detailed Information

 

Management

 

Job Description

Title

Name

Sex

Nationality

Inauguration Day

President

Mr.

Koo Ja-Choon

Male

Korean

02/15/2000

Director

Mr.

Koo Dae-Ho

Male

Korean

02/15/2000

Director

Mr.

Yom Chang-Yong

Male

Korean

03/31/2006

Director

Mr.

Lee Jae-Man

Male

Korean

03/31/2006

Auditor

Mr.

Song Gang-Sub

Male

Korean

02/15/2000

 

 

Financials

Unit: KRW

Year

Sales

Assets

Net income

2005

 

 

 

2004

 

 

 

2003

 

 

 

2002

 

 

 

 

 

Financial Description

Unit: KRW

Authorized Capital

3,200,000,000

Paid-Up Capital

2,000,000,000

Total Issued Shares

200,000

 

Balance Sheet                           Unit: Million KRW

 

2003

2002

12/31/2001

Total Assets

 

 

5,911

Current Assets

 

 

3,616

Quick assets

 

 

684

Inventories

 

 

2,932

Fixed Assets

 

 

2,295

Investments

 

 

20

Tangibles

 

 

2,257

Intangibles

 

 

18

Total Liabilities

 

 

4,917

Current Liabilities

 

 

3,820

Fixed Liabilities

 

 

1,097

Capital Stock

 

 

2,000

Capital Surplus

 

 

 

Profit Surplus

 

 

-1,006

Capital Adjustment

 

 

 

Total Equity

 

 

994

Total Liabilities & Equity

 

 

5,911

 

                                                Income Statement                        Unit Million KRW

 

2003

2002

12/31/2001

Sales

 

 

5,998

Cost of Sold Goods

 

 

5,777

Gross Profit

 

 

221

Selling & Admin. Expenses

 

 

257

Operating Income

 

 

-36

Non-Operating Income

 

 

60

Non-Operating expenses

 

 

347

Ordinary Income

 

 

-323

Special Income

 

 

129

Special Loss

 

 

11

Income Before Taxes

 

 

-205

Income Taxes Expenses

 

 

-

Net Income

 

 

-205

Bank Details

Industrial Bank of Korea

Corporate Registered No.

110111-1347122

Business Registered No.

220-81-40376

Permit & Licenses

 

Shareholder Position

 

Company History

2002

 Produced TACA

 Produced Bucillamine

 Produced Bambutenol

 Produced Alibendol

 

2001

 Extended a Plant 1

 Produced Zidovudine

 Produced Cefotazidime 

 

2000

 Produced TAEM

 Produced TDA

 Produced Cefazedone

 Produced TACA

 Produced Cefatrizine-PG 

 

1999

 Completed the Central Research Laboratories

 Extended a Plant 1

 Produce Ceftriaxone(TEA)

 Produced PYCA.HI

 Produced MAEM

 Produced Cefotaxime

 Produced Cefoperazone

 Produced AT-TBA

 

1998

 Produced Ceftriaxone

 Produced Cycloserine

 Produced PYCA

 

1997

 Produced Talniflumate

 Produced 7-ACT

 Produced Tramado

 Produced Mefenamic

 Produced Albendazol 

 

1996

 Completed plant 1 for synthesis raw material

 

 

Products, Technologies, Services Description

 

Main Products & Services

 

Detailed Products Spec.

Therapeutic Category

Product

Spec.

Remark

Intermediate for Cephalosporin Antibiotic

TACA

 

CTZ.PG

7-ACT

 

CFTX-Na

AT-TBA

 

TAEM

MAEM

 

CFTX-Na, CTX-Na

PYCA.2HCl

 

Ceftazidime

PYCA.HI

 

Ceftazidime

TDA

 

Cefazedon

TAEM

 

Ceftazidime

TMCA

 

Cefoperazone

Antiviral for AIDS Therapy

AZT

BP98

 

Cephalosporin Antibiotic

Cefoperazone. Sod.

USP23, JP13

 

Cefoperazone. Free Acid

 

 

Ceftriaxone. Sod.

USP23

 

Cefotaxime. Sod.

USP23

 

Cefotaxime. Free Acid

 

 

Cefaclor

USP23

 

Cefatrizine P.G.

JP13

 

Cefotiam.2HCl

USP23, JP13

 

Cefazedone. Free Acid

 

 

Cefazedone. Sod.

 

 

Ceftazidime

USP23

 

Ceftazidine.2HCl

 

 

Ceftezole

Intl. Standard

 

Cefuroxim axetil

 

 

Quinolone Chemotherapeutic

Ciprofloxacin. HCl

USP23

 

Antituberculous

Cycloserine

USP23

 

Anti-inflammatory

Loxoprofen. HCl

JP13

 

Sulfonamide for

Sulfisozole. Sod.

Intl. Standard

 

Fishery Culture

Analgesic

Tramadol. HCl

Intl. Standard

 

Cephalosporin Antibiotic

Cefuminox sodium

 

 

Technologies Acquired

 

 

 

Organization Structure

 

Suppliers

 

Customers

 

Competitors

 

 

 

Related Parties (Subsidiaries, Joint-Venture & Affiliates)

 

Affiliates

Hawon Pharm Co,.Ltd. (www.hawonpharm.co.kr)

Overseas Office

 

Liaison Office

 

Overseas Branch

 

Join Venture

 

Subsidiary

 

Corporate Ownership

 

Major Shareholders

 

Cooperative Enterprise

 

 

 

Sales Spread

 

Unit : Mil KRW　

2005

2004

2003

Export

 

 

 

Domestic

 

 

 

Total

 

 

 

 

 

RATING EXPLANATIONS

 

 

RATING

STATUS

PROPOSED CREDIT LINE

>86

Aaa

Possesses an extremely sound financial base with the strongest capability for timely payment of interest and principal sums

Unlimited

71-85

Aa

Possesses adequate working capital. No caution needed for credit transaction. It has above average (strong) capability for payment of interest and principal sums

Large

56-70

A

Financial & operational base are regarded healthy. General unfavourable factors will not cause fatal effect. Satisfactory capability for payment of interest and principal sums

Fairly Large

41-55

Ba

Overall operation is considered normal. Capable to meet normal commitments.

Satisfactory

26-40

B

Unfavourable & favourable factors carry similar weight in credit consideration. Capability to overcome financial difficulties seems comparatively below average/normal.

Small

11-25

Ca

Adverse factors are apparent. Repayment of interest and principal sums in default or expected to be in default upon maturity

Limited with full security

<10

C

Absolute credit risk exists. Caution needed to be exercised

Credit not recommended

 

 

 

PRIVATE & CONFIDENTIAL : This information is provided to you at your request, you having employed MIPL for such purpose. You will use the information as aid only in determining the propriety of giving credit and generally as an aid to your business and for no other purpose. You will hold the information in strict confidence, and shall not reveal it or make it known to the subject persons, firms or corporations or to any other. MIPL does not warrant the correctness of the information as you hold it free of any liability whatsoever. You will be liable to and indemnify MIPL for any loss, damage or expense, occasioned by your breach or non observance of any one, or more of these conditions